Webcast: Optimal Use of Autologous Transplantation and Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin's Lymphoma

The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving. There is considerable debate regarding the timing and number of transplants for MM and the indications for transplant in NHL. The optimal use of transplant in the disease course and appropriate mobilization could drastically change the treatment of MM and NHL. This program serves as a medium to give physicians a chance to recognize these changes.

Here is the link to the Activity:  https://www.bloodline.net/optimal-use-of-autologous-transplantation-and-stem-cell-mobilization-in-patients/

Target Audience

This activity has been developed and is intended for transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

  •  Identify existing and emerging strategies for optimizing stem cell transplantation in MM and NHL
  •  Evaluate current data on stem cell mobilization in patients with MM and Hodgkin’s disease 
  •  Determine the factors that affect and optimize the efficacy of stem cell mobilization
Additional information

CME Coordinator Contact Information

Name: 
David Utz
Phone Number: 
+1 (434) 989-9664
Email: 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
06/07/2018
Course expires: 
06/07/2019
Cost:
$0.00

Role of Transplantation in MM and Mobilization Strategies
Luciano Costa, MD, PhD
University of Alabama at Birmingham
Birmingham, AL

Role of transplantation in NHL and Mobilization Strategies
Parameswaran Hari, MD, MRCP, MS
Medical College of Wisconsin
Milwaukee, WI

This activity is supported by educational grants from Sanofi Genzyme.

Parameswaran Hari, MD, MRCP, MS (Chair)
Armand Quick-William Stapp Professor of Hematology
Interim Chief Hematology and Oncology
Medical College of Wisconsin, Milwaukee, WI

Parameswaran Hari, MD, MRCP, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief of the Division of Hematology and Oncology in the Department of Medicine. After medical school in India, he completed training in Internal Medicine and Hematology at premier institutions in United Kingdom, and then in Medical Oncology and Transplantation at the Medical College of Wisconsin.  Dr. Hari is also Scientific Director of the plasma cell disorders working committees of the Center for International Blood and Marrow Transplant Research (CIBMTR). His primary clinical interests are in allogeneic hematopoietic stem cell transplantation, plasma cell disorders—multiple Myeloma, Amyloidosis, and other monoclonal gammopathies.


Luciano J. Costa, MD, PhD
Department of Medicine and Bone Marrow
Transplantation and Cell Therapy Program
University of Alabama, Birmingham, Birmingham, AL

Luciano J. Costa, MD, PhD, is originally from Brazil, where he graduated from medical school in 1998 and subsequently completed a PhD studying cell signaling in cancer, both at Universidade de Sao Paulo. He trained in Internal Medicine and Hematology prior to moving to the U.S. in 2003 to pursue fellowships in Hematology and Oncology (University of Colorado) and Blood and Marrow Transplantation (Mayo Clinic, Rochester), and ultimately a career as clinical investigator.  Prior to joining the University of Alabama at Birmingham, he held an appointment as Associate Professor of Medicine and Director of Research for the Blood and Marrow Transplant Program at the Medical University of South Carolina from 2008 to 2014. His prior clinical research includes transplant and non-transplant management of lymphoproliferative and plasma cell disorders. He has also been deeply engaged in strategies for optimization of hematopoietic progenitor cells mobilization and in population outcomes of blood cancers.


Faculty and Planner Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

James Ferrara, MD, DSc discloses that he has a GVHD biomarker patent from which he receives a royalty.

Motoko Koyama, MD, PhD has no relevant conflicts of interest to disclose.

Ernst Holler, MD, PhD discloses that he serves on the advisory board for Pharmacyclics. He also has received honoraria from Prime Oncology and Sanofi.

The educational content of this program has been peer reviewed by The Medical College of Wisconsin.

The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership
of The Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement
The Medical College of Wisconsin designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in these activities.

Hours of Participation for Allied Health Care
Professionals: The Medical College of Wisconsin designates the live activity for up to 1.0 hours for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
06/07/2018
Course expires: 
06/07/2019

Price

Cost:
$0.00
Please login or register to take this course.